Assertio Holdings has announced the successful completion of its previously announced merger with Zydus Lifesciences pursuant to the terms of the Agreement and Plan of Merger, dated as of May 13, 2026, between, among others, the company, Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirates (UAE) and a wholly-owned subsidiary of Zydus Lifesciences and Zara Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Zydus and Zydus Lifesciences.

Assertio will continue to operate as a wholly-owned subsidiary of Zydus Lifesciences.

Assertio also has delivered a notice to holders of its 6.50 percent Convertible Senior Notes due 2027, pursuant to the Indenture, dated as of August 25, 2022, between the company and US Bank Trust Company, National Association, as Trustee, notifying holders of the Notes that, as a result of the consummation of the merger, pursuant to the terms of the Merger Agreement, a ‘Fundamental Change,’ a ‘Make-Whole Fundamental Change’ and a ‘Merger Event,’ each as defined in the Indenture, occurred effective as of June 16, 2026.

As a result of the Fundamental Change, holders of the Notes have the right to require the company to repurchase for cash (i) all of such holder’s notes or (ii) any portion of the principal amount thereof that is equal to USD 1,000 or an integral multiple of USD 1,000, in each case, on July 17, 2026 at a repurchase price equal to 100 percent of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest thereon, if any, to, but excluding, the Fundamental Change Repurchase Date.